Last updated: March 8, 2024
Sponsor: Muhammad
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Asperger's Disorder
Williams Syndrome
Autism
Treatment
Injection
Routine therapy
Lidocaine Hydrochloride
Clinical Study ID
NCT06301685
SGB-AST
Ages 3-6 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosed as Autistic Disorder.
- Aged between 3 years old and 6 years old.
- No contraindications to stellate ganglion block.
Exclusion
Exclusion Criteria:
- Other significant physical or neurodevelopmental disorders.
- Other significant medical conditions
Study Design
Total Participants: 80
Treatment Group(s): 3
Primary Treatment: Injection
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Thai-Z Uni Hospital
Bangkok,
ThailandSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.